Corticotropin-releasing factor (CRF, nomenclature as agreed by the NC-IUPHAR subcommittee on Corticotropin-releasing Factor Receptors [7]) receptors are activated by the endogenous peptides corticotrophin-releasing hormone (CRH, P06850), a 41 amino-acid peptide, urocortin 1 (UCN, P55089), 40 amino-acids, urocortin 2 (UCN2, Q96RP3), 38 amino-acids and urocortin 3 (UCN3, Q969E3), 38 amino-acids. CRF₁ and CRF₂ receptors are activated non-selectively by corticotrophin-releasing hormone (CRH, P06850) and urocortin 1 (UCN, P55089). Binding to CRF receptors can be conducted using [¹²⁵I]Tyr⁰-CRF or [¹²⁵I]Tyr⁰-sauvagine with K_d values of 0.1-0.4 nM. CRF₁ and CRF₂ receptors are non-selectively antagonized by α-helical CRF, D-Phe-CRF-(12-41) and astressin.

A CRF binding protein has been identified (CRHBP, P24387) to which both corticotrophin-releasing hormone (CRH, P06850) and urocortin 1 (UCN, P55089) bind with high affinities, which has been suggested to bind and inactivate circulating corticotrophin-releasing hormone (CRH, P06850) [11].

* Key recommended reading is highlighted with an asterisk

Binder EB, Nemeroff CB. (2010) The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol. Psychiatry, 15 (6): 574-88. [PMID:20010888]

Bonci A, Borgland S. (2009) Role of orexin/hypocretin and CRF in the formation of drug-dependent synaptic plasticity in the mesolimbic system. Neuropharmacology, 56 Suppl 1: 107-11. [PMID:18694770]

Cruceanu C, Schmouth JF, Torres-Platas SG, Lopez JP, Ambalavanan A, Darcq E, Gross F, Breton B, Spiegelman D, Rochefort D et al.. (2017) Rare susceptibility variants for bipolar disorder suggest a role for G protein-coupled receptors. Mol. Psychiatry,  [Epub ahead of print]. [PMID:29158579]

Fekete EM, Zorrilla EP. (2007) Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol, 28 (1): 1-27. [PMID:17083971]

* Grammatopoulos DK. (2012) Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction. Br. J. Pharmacol., 166 (1): 85-97. [PMID:21883143]

* Gysling K. (2012) Relevance of both type-1 and type-2 corticotropin releasing factor receptors in stress-induced relapse to cocaine seeking behaviour. Biochem. Pharmacol., 83 (1): 1-5. [PMID:21843515]

* Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM. (2003) International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev., 55: 21-26. [PMID:12615952]

Kehne JH, Cain CK. (2010) Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models. Pharmacol. Ther., 128 (3): 460-87. [PMID:20826181]

Koob GF. (2010) The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res., 1314: 3-14. [PMID:19912996]

Taché Y, Bonaz B. (2007) Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. J. Clin. Invest., 117 (1): 33-40. [PMID:17200704]

Tsatsanis C, Dermitzaki E, Venihaki M, Chatzaki E, Minas V, Gravanis A, Margioris AN. (2007) The corticotropin-releasing factor (CRF) family of peptides as local modulators of adrenal function. Cell. Mol. Life Sci., 64 (13): 1638-55. [PMID:17453142]

* Valentino RJ, Bangasser D, Van Bockstaele EJ. (2013) Sex-biased stress signaling: the corticotropin-releasing factor receptor as a model. Mol. Pharmacol., 83 (4): 737-45. [PMID:23239826]

Wise RA, Morales M. (2010) A ventral tegmental CRF-glutamate-dopamine interaction in addiction. Brain Res., 1314: 38-43. [PMID:19800323]

* Zhu H, Wang J, Li J, Li S. (2011) Corticotropin-releasing factor family and its receptors: pro-inflammatory or anti-inflammatory targets in the periphery?. Inflamm. Res., 60 (8): 715-21. [PMID:21476084]

Ziegler CG, Krug AW, Zouboulis CC, Bornstein SR. (2007) Corticotropin releasing hormone and its function in the skin. Horm. Metab. Res., 39 (2): 106-9. [PMID:17326006]

1. Chaki S, Okuyama S, Nakazato A, Kumagai T, Okubo T, Ikeda Y, Oshida Y, Hamajima Y, Tomisawa K. (1999) In vitro pharmacological profile of nonpeptide CRF1 receptor antagonists, CRA1000 and CRA1001. Eur. J. Pharmacol., 371 (2-3): 205-11. [PMID:10357258]

2. Chen C, Dagnino R, De Souza EB, Grigoriadis DE, Huang CQ, Kim KI, Liu Z, Moran T, Webb TR, Whitten JP et al.. (1996) Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J. Med. Chem., 39 (22): 4358-60. [PMID:8893829]

3. Chen YL, Obach RS, Braselton J, Corman ML, Forman J, Freeman J, Gallaschun RJ, Mansbach R, Schmidt AW, Sprouse JS et al.. (2008) 2-aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonists. J. Med. Chem., 51 (5): 1385-92. [PMID:18288792]

4. Dautzenberg FM, Gutknecht E, Van der Linden I, Olivares-Reyes JA, Dürrenberger F, Hauger RL. (2004) Cell type specific calcium signaling by corticotropin-releasing factor type 1 (CRF1) and 2a (CRF2(a)) receptors: Gq coupling in human embryonic kidney 293 but not SK-N-MC neuroblastoma cells. Biochem Pharmacol., 68: 1833-1844. [PMID:15450949]

5. Dautzenberg FM, Py-Lang G, Higelin J, Fischer C, Wright MB, Huber G. (2001) Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences. J Pharmacol Exp Ther., 296: 113-120. [PMID:11123370]

6. Gully D, Geslin M, Serva L, Fontaine E, Roger P, Lair C, Darre V, Marcy C, Rouby PE, Simiand J et al.. (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther., 301 (1): 322-32. [PMID:11907190]

7. Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM. (2003) International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev., 55: 21-26. [PMID:12615952]

8. He L, Gilligan PJ, Zaczek R, Fitzgerald LW, McElroy J, Shen HS, Saye JA, Kalin NH, Shelton S, Christ D et al.. (2000) 4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist. J. Med. Chem., 43 (3): 449-56. [PMID:10669572]

9. Lawrence AJ, Krstew EV, Dautzenberg FM, Rühmann A. (2002) The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain. Br. J. Pharmacol., 136 (6): 896-904. [PMID:12110614]

10. Lundkvist J, Chai Z, Teheranian R, Hasanvan H, Bartfai T, Jenck F, Widmer U, Moreau JL. (1996) A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur. J. Pharmacol., 309 (2): 195-200. [PMID:8874139]

11. Perkins AV, Wolfe CD, Eben F, Soothill P, Linton EA. (1995) Corticotrophin-releasing hormone-binding protein in human fetal plasma. J. Endocrinol., 146 (3): 395-401. [PMID:7595134]

12. Rühmann A, Chapman J, Higelin J, Butscha B, Dautzenberg FM. (2002) Design, synthesis and pharmacological characterization of new highly selective CRF(2) antagonists: development of 123I-K31440 as a potential SPECT ligand. Peptides, 23 (3): 453-60. [PMID:11835994]

13. Webster EL, Lewis DB, Torpy DJ, Zachman EK, Rice KC, Chrousos GP. (1996) In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology, 137 (12): 5747-50. [PMID:8940412]

14. Zobel AW, Nickel T, Künzel HE, Ackl N, Sonntag A, Ising M, Holsboer F. (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res, 34 (3): 171-81. [PMID:10867111]

Subcommittee members: Richard L. Hauger (Chairperson) VA Healthcare System and Department of Psychiatry University of California San Diego 9500 Gilman Drive La Jolla CA 92093-0603 USA Frank M. Dautzenberg (Chairperson) CNS Research Johnson & Johnson Research & Development Turnhoutseweg 30, Discovery Research Center -020, Room 1L6 Beerse B-2340 Belgium Dimitri E. Grigoriadis Neurocrine Biosciences Inc. 10555 Science Center Dr. San Diego California 92121 USA Victoria B. Risbrough UC San Diego Department of Psychiatry 9500 Gilman Drive, MC 0603 La Jolla, CA 92093-0603 Rita J. Valentino Children's Hospital of Philadelphia 3615 Civic Center Blvd. Abramson Bldg., 402C Philadelphia, PA 19104

Other contributors: Thomas Steckler CNS Research Johnson & Johnson Research & Development Turnhoutseweg 30, Discovery Research Center -020, Room 1L6 Beerse B-2340 Belgium Wylie W. Vale (1941-2012) formally of The Salk Institute, La Jolla, California